Analysts at UOB Kay Hian project that Alibaba Health Information Technology Ltd. will sustain robust revenue and profit growth over the next three fiscal years, following better-than-expected results for the first half of FY26.

Key Forecasts and Drivers:

• Growth Outlook: The analysts forecast compound annual growth rates (CAGR) of 13% for revenue and 24% for adjusted net profit from FY26 to FY28.
• Near-Term Targets: The company has reaffirmed its FY26 targets of 10%-15% revenue growth and 20%-30% adjusted net profit growth year-on-year.
• Growth Drivers: This expansion is expected to be fueled by:
  1. Sustained momentum in innovative drug sales.
  2. Deepened synergies with parent Alibaba Group.
  3. Increased adoption of artificial intelligence across its services.

Rating and Target:
UOB Kay Hian maintains a “Buy” rating on the stock with a target price of HK$7.80. Despite the positive outlook, shares fell 2% to HK$5.40 in recent trading.